HCPCS Level II code J9215 denotes the injection of interferon alfa-n3 (human leukocyte derived), 250,000 IU. This biologic injectable is used in therapeutic settings where interferon alfa-n3 is clinically indicated. Nationally, J9215 matters because it represents a specialty injectable medication with implications for drug acquisition, site-of-service selection, and payer coverage policy for biologic therapies.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for interferon alfa-n3 administration, expected sites of service, and the service line classification. The publication provides benchmarks and payment context for the code, highlights relevant policy considerations affecting coverage and billing for injectable biologics, and summarizes common billing modifiers used with specialty drug injections.

The report addresses billing practices and reimbursement considerations at a national level, equips billing staff and administrators with code-specific information, and outlines where to find more detailed payer-specific guidance. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.